What question did this study set out to answer?

This research examines how hormone receptors influence gasdermin E expression and its role in breast cancer cell death and anti-tumor immunity.

May 31, 2026Open Access

Estrogen /progesterone receptor-gasdermin E axis links hormone signalling to pyroptotic cell death, anti-tumour immunity and response to chemotherapy in breast cancer cells

Key Points

This research examines how hormone receptors influence gasdermin E expression and its role in breast cancer cell death and anti-tumor immunity.
Examined gasdermin E levels after hormone receptor inhibition using immunofluorescence and LDH release assays.
Studied regulatory effects with PCR, chromatin immunoprecipitation, and dual luciferase assays.
Analyzed GSDME's effect on Doxorubicin sensitivity using sulforhodamine B and explored immune cell interactions in patient samples.
Estrogen and progesterone receptors repress GSDME in hormone receptor-positive breast cancer cells.
Inhibition of hormone receptors significantly increased GSDME levels, leading to pyroptosis induction.
Enhanced immune activation was observed, including increased NK cell cytotoxicity and T cell infiltration.

Abstract

Hormone receptor signalling orchestrates different pathways in breast cancer (BC). Gasdermin E (GSDME), a key pyroptosis-inducing protein, has emerged as an important modulator of immunogenic cell death and anti-tumor immunity. We aim to investigate the regulatory and functional implications of the relationship between hormone receptors and GSDME expression in BC. The impact of hormone receptor inhibition/downregulation on GSDME level and activity was studied by immunofluorescence and lactate dehydrogenase release assay. The potential regulatory role of hormone receptors was tested by polymerase chain reaction, chromatin immunoprecipitation and dual luciferase reporter assay, while the influence of GSDME on the sensitivity of BC cell lines to doxorubicin was studied by sulforhodamine B. The impact of GSDME on cytotoxic immune cells was studied in patient samples. A mass spectroscopic analysis was done to define the pathways affected by GSDME downregulation. Our findings herein demonstrate for the first time that estrogen and progesterone receptors act as transcription repressors of GSDME in hormone receptor-positive BC cells. Pharmacological/biological inhibition of hormone receptors, led to a significant upregulation of GSDME, which facilitated its cleavage, membrane translocation of its N-terminal fragment and subsequent induction of pyroptosis. These events were accompanied by enhanced immune cell activation, including increased natural killer (NK) cell cytotoxicity and a favourable T cell infiltration. Collectively, our findings uncover a novel ER/PR-GSDME regulatory axis linking hormone receptor signalling to pyroptosis, chemosensitivity, and components of anti-tumor immunity in BC. This work highlights GSDME as a predictive biomarker for combination therapies involving hormone receptor inhibitors, chemotherapy, and immune checkpoint inhibitors (ICIs) in BC.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper